IL-2Rγ binding compounds
IL-2Rβ ligands and IL-2Rγc ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2Rβ ligands and/or the IL-2Rγc ligands can be IL-2 receptor agonists.
1. An IL-2Rγc ligand, wherein,
the IL-2Rγc ligand exhibits a binding affinity (IC 50 ) to the human IL-2Rγc subunit of less than 100 μM; and
the IL-2Rγc ligand comprises the amino acid sequence of any one of SEQ ID NOS: 200, 206, 904-906, 214, 227, 233, 917, 920, 236-240, 252-254, 921-922, 265-266, 934, 937, 939, 943-948, 954, 965, 991, 1007, and 1024:
SEQ ID NO: 200
R I C Q D F Q G V I L C W L
SEQ ID NO: 206
G T C Q E Y N G V M I C W G
SEQ ID NO: 904
I H C N S Q M G I L I C W Y
SEQ ID NO: 905
I M C D S S S G V S I C W T
SEQ ID NO: 906
I T C Q T F N G V P L C W K
SEQ ID NO: 214
Q I C Q E W S G V N L C W H
SEQ ID NO: 227
P A C Q D W N G V E L C I L
SEQ ID NO: 233
F T C W D Y N G V D L C Q I
SEQ ID NO: 917
V M C E L F D E V E L C W F
SEQ ID NO: 920
V E C D V Y H G V E I C W A
SEQ ID NO: 236
M C W L E W G E W V G S C L
SEQ ID NO: 237
L C F S E F L G E W V D C N
SEQ ID NO: 238
V C S F D E A W G E W I C E
SEQ ID NO: 239
D C P Q V S W Y E W L D C Y
SEQ ID NO: 240
Y C L F D E Q M G E W L C H
SEQ ID NO: 252
W C L S Q E E F N F L V
SEQ ID NO: 253
Y S E E L S W I C K Q L
SEQ ID NO: 254
I D M Y P Q E W W F C N
SEQ ID NO: 921
L S L G Q K D W W L I L
SEQ ID NO: 922
Q L Q G L C D F F W A H
SEQ ID NO: 265
C G I A Y R S G E F T M I C
SEQ ID NO: 266
C P S M L Q G P E R T W V C
SEQ ID NO: 934
C F I R F Y Q D K Y D Y V C
SEQ ID NO: 937
C F V M Y K N N E F S L I C
SEQ ID NO: 939
C L I Y K E Q K F A L I E C
SEQ ID NO: 943
K M N K C A T P S Q C S V I F
SEQ ID NO: 944
N L N K C W N P R S C S S K F
SEQ ID NO: 945
T Y N K C R S P F E C S G I F
SEQ ID NO: 946
Y L N K C Y S P S S C Q L R L
SEQ ID NO: 947
S L Y K C N S P L S C S N I F
SEQ ID NO: 948
S L L K C Y N A S T C A S V F
SEQ ID NO: 954
L A L R K E V V C Q E Y Y G V E L C W I
SEQ ID NO: 965
V V C Q D W E G V E L C W Q
SEQ ID NO: 991
R P Q I E C Q E W Q G V E L C W T R E E
SEQ ID NO: 1007
T D E V S C Q E W E G V E L C W I E R Q
SEQ ID NO: 1024
R T G V E C Q D W H G V E L C W P V W E.
2. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NO: 200.
3. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NO: 206.
4. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NOS: 904-906.
5. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NO: 214.
6. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NO: 227.
7. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NO: 233.
8. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NO: 917.
9. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NO: 920.
10. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NOS: 236-240.
11. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NOS: 252-254.
12. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NOS: 921-922.
13. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NO: 265.
14. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NO: 266.
15. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NO: 934.
16. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NO: 937.
17. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NO: 939.
18. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NO: 943-948.
19. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NO: 954.
20. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NO: 965.
21. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NO: 991.
22. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NO: 1007.
23. The IL-2Rγc ligand of claim 1 , wherein the IL-2Rγc ligand comprises an amino acid sequence of SEQ ID NO: 1024.
24. A compound comprising at least one IL-2Rγc ligand of claim 1 .
25. The compound of claim 24 , wherein the compound is selected from a peptide, a conjugate, and a fusion protein.
26. A pharmaceutical composition comprising the IL-2Rγc ligand of claim 1 .
27. A pharmaceutical composition comprising the compound of claim 26 .